RSS Feeds
The Biological Properties of Etiocholanolone
Combined Clinical Staff Conference at the National Institutes of Health
- SHELDON M. WOLFF, M.D., F.A.C.P.Bethesda, Maryland ;
- HARRY R. KIMBALL, M.D.;
- SEYMOUR PERRY, M.D., F.A.C.P.;
- RICHARD ROOT, M.D.Bethesda, Maryland ; and
- ATTALLAH KAPPAS, M.D., F.A.C.P.New York, New York
- Requests for reprints should be addressed to Sheldon M. Wolff, M.D., Acting Clinical Director, National Institute of Allergy and Infectious Diseases, Bldg. 10, Room 11N-313, National Institutes of Health, Bethesda, Md. 20014.
Excerpt
Dr. Sheldon M. Wolff: In 1956 Dr. Attallah Kappas and Hellman, Fukushima, and Gallagher (1) first reported that the steroid metabolite etiocholanolone caused fever when it was administered to man. Subsequent work by the same investigators and others has substantiated the pyrogenic properties of etiocholanolone (2) and other 5 beta-H C19, C21, and C24 steroids (3). These observations are especially noteworthy since they describe biologic activity possessed by a class of compounds previously thought to be physiologically inert and since they represent the first discovery of pyrogenic substances of endogenous origin in man. Interest in etiocholanolone was heightened considerably by
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
This is an edited transcription of a Combined Clinical Staff Conference at the Clinical Center, Bethesda, Md., by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service, U. S. Department of Health, Education, and Welfare.
-
- Received September 26, 1967.
- Accepted September 29, 1967.
